9月25日，益诺思涨5.11%，截至发稿，报50.80元/股，成交5201.80万元，换手率1.15%，总市值71.62亿 元。 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自由贸易试验区郭守敬路199号106室，成 立日期2010年5月12日，上市日期2024年9月3日，公司主营业务涉及专业提供生物医药非临床研究服务 为主的综合研发服务(CRO)。主营业务收入构成为：非临床96.31%，临床3.42%，其他0.27%。 从益诺思十大流通股东角度 数据显示，嘉实基金旗下1只基金位居益诺思十大流通股东。嘉实医药健康股票A（005303）二季度新 进十大流通股东，持有股数34.43万股，占流通股的比例为1.22%。根据测算，今日浮盈赚取约85.05万 元。 嘉实医药健康股票A（005303）基金经理为孙晓晖、郝淼。 截至发稿，孙晓晖累计任职时间168天，现任基金资产总规模9.85亿元，任职期间最佳基金回报 39.35%， 任职期间最差基金回报38.84%。 郝淼累计任职时间6年254天，现任基金资产总规模36.52亿元，任职期间最佳基金回报183.83%， 任职 期间最差基金回报-29.32%。 风险 ...

嘉实医药健康股票A（005303）基金经理为孙晓晖、郝淼。 截至发稿，孙晓晖累计任职时间160天，现任基金资产总规模9.85亿元，任职期间最佳基金回报 41.81%， 任职期间最差基金回报41.31%。 郝淼累计任职时间6年246天，现任基金资产总规模36.52亿元，任职期间最佳基金回报183.83%， 任职 期间最差基金回报-27.96%。 9月17日，益诺思涨5.01%，截至发稿，报45.28元/股，成交1.21亿元，换手率3.06%，总市值63.84亿 元。益诺思股价已经连续5天上涨，区间累计涨幅14.8%。 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自由贸易试验区郭守敬路199号106室，成 立日期2010年5月12日，上市日期2024年9月3日，公司主营业务涉及专业提供生物医药非临床研究服务 为主的综合研发服务(CRO)。主营业务收入构成为：非临床96.31%，临床3.42%，其他0.27%。 从益诺思十大流通股东角度 数据显示，嘉实基金旗下1只基金位居益诺思十大流通股东。嘉实医药健康股票A（005303）二季度新 进十大流通股东，持有股数34.43万股，占流通股的比例为1.22%。根 ...

Company Overview - Yinos Biotech Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company is set to be listed on September 3, 2024. Its main business involves providing comprehensive research and development services (CRO) focused on non-clinical research services in the biopharmaceutical sector [1] - The revenue composition of Yinos is as follows: non-clinical services account for 95.42%, clinical services for 4.11%, and other services for 0.47% [1] Stock Performance - On September 1, Yinos shares increased by 5.1%, reaching a price of 40.98 CNY per share, with a trading volume of 30.95 million CNY and a turnover rate of 2.75%. The total market capitalization is 5.777 billion CNY [1] Shareholder Information - Among the top ten circulating shareholders of Yinos, one fund from Harvest Fund Management, the Harvest Medical Health Stock A (005303), entered the top ten in the second quarter, holding 344,300 shares, which represents 1.22% of the circulating shares. The estimated floating profit for today is approximately 685,200 CNY [2] - The Harvest Medical Health Stock A fund was established on December 4, 2017, with a current size of 786 million CNY. Year-to-date returns are 42.3%, ranking 534 out of 4222 in its category. Over the past year, returns are 50.75%, ranking 1765 out of 3779, and since inception, the fund has achieved a return of 93.9% [2] Fund Management - The fund manager for Harvest Medical Health Stock A is Sun Xiaohui, who has been in position for 144 days, with a total fund size of 985 million CNY. The best return during his tenure is 37.64%, while the worst is 37.22% [3] - The other fund manager, Hao Miao, has been in position for 6 years and 230 days, managing a total fund size of 3.652 billion CNY. His best return during his tenure is 183.83%, while the worst is -30.4% [3]